ABSTRACT
The plasma proteins factor XII (FXII) and prekallikrein (PK) undergo reciprocal activation to the proteases FXIIa and kallikrein by a process that is enhanced by surfaces (contact activation) and regulated by the serpin C1 inhibitor. Kallikrein cleaves high-molecular-weight kininogen (HK), releasing the vasoactive peptide bradykinin. Patients with hereditary angioedema (HAE) experience episodes of soft tissue swelling as a consequence of unregulated kallikrein activity or increased prekallikrein activation. Although most HAE cases are caused by reduced plasma C1-inhibitor activity, HAE has been linked to lysine/arginine substitutions for Thr309 in FXII (FXII-Lys/Arg309). Here, we show that FXII-Lys/Arg309 is susceptible to cleavage after residue 309 by coagulation proteases (thrombin and FXIa), resulting in generation of a truncated form of FXII (δFXII). The catalytic efficiency of δFXII activation by kallikrein is 15-fold greater than for full-length FXII. The enhanced rate of reciprocal activation of PK and δFXII in human plasma and in mice appears to overwhelm the normal inhibitory function of C1 inhibitor, leading to increased HK cleavage. In mice given human FXII-Lys/Arg309, induction of thrombin generation by infusion of tissue factor results in enhanced HK cleavage as a consequence of δFXII formation. The effects of δFXII in vitro and in vivo are reproduced when wild-type FXII is bound by an antibody to the FXII heavy chain (HC; 15H8). The results contribute to our understanding of the predisposition of patients carrying FXII-Lys/Arg309 to angioedema after trauma, and reveal a regulatory function for the FXII HC that normally limits PK activation in plasma.
Subject(s)
Factor XII/chemistry , Factor XIa/chemistry , Hereditary Angioedema Type III/blood , Hereditary Angioedema Type III/genetics , Angioedemas, Hereditary , Animals , Arginine/chemistry , Blood Coagulation , Bradykinin/blood , Catalysis , Complement C1 Inhibitor Protein/chemistry , Factor XIIa/chemistry , HEK293 Cells , Humans , Kininogens/blood , Lysine/chemistry , Mice , Mice, Inbred C57BL , Plasma Kallikrein/chemistry , Prekallikrein/chemistry , Protein Binding , Recombinant Proteins/chemistry , Surface Properties , Thrombin/geneticsABSTRACT
Hereditary angioedema with normal C1 esterase inhibitor and mutations in the F12 gene (HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. It occurs nearly exclusively in women. We report our experience treating HAE-FXII with discontinuation of potential trigger factors and drug therapies. The study included 72 patients with HAE-FXII. Potential triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors. Drug treatment comprised plasma-derived C1 inhibitor (pdC1-INH) for acute swelling attacks and progestins, tranexamic acid, and danazol for the prevention of attacks. Discontinuation of eOC was effective in 25 (89.3%) of 28 women and led to a reduction in the number of attacks (about 90%). After ending hormonal replacement therapy, three of eight women became symptom-free. Three women with exacerbation of HAE-FXII during intake of quinapril or enalapril had no further HAE-FXII attacks after discontinuation of those drugs. Eleven women were treated with pdC1-INH for 143 facial attacks. The duration of the treated facial attacks (mean: 26.6 h; SD: 10.1 h) was significantly shorter than that of the previous 88 untreated facial attacks in the same women (mean: 64.1 h; SD: 28.0 h; P < 0.01). The mean reduction in attack frequency was 99.8% under progestins after discontinuing eOC (16 women), 93.8% under tranexamic acid (four women), and 100% under danazol (three women). For patients with HAE-FXII, various treatment options are available which completely or at least partially reduce the number or duration of attacks.
Subject(s)
Complement C1 Inhibitor Protein/therapeutic use , Hereditary Angioedema Type III/drug therapy , Adolescent , Adult , Aged , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Biomarkers , Chemoprevention , Child , Disease Progression , Estrogens/adverse effects , Factor XII/genetics , Female , Hereditary Angioedema Type III/blood , Hereditary Angioedema Type III/diagnosis , Hereditary Angioedema Type III/genetics , Humans , Male , Middle Aged , Mutation , Risk Factors , Treatment Outcome , Young AdultSubject(s)
DNA Mutational Analysis , Factor XII/genetics , Genetic Testing/methods , Hereditary Angioedema Type III/genetics , Mutation , Adult , Female , Genetic Markers , Genetic Predisposition to Disease , Hereditary Angioedema Type III/blood , Hereditary Angioedema Type III/diagnosis , Hereditary Angioedema Type III/immunology , Hereditary Angioedema Type III/therapy , Humans , Phenotype , Predictive Value of Tests , Risk Factors , Tomography, X-Ray ComputedABSTRACT
Combinations of proinflammatory and procoagulant reactions are the unifying principle for a variety of disorders affecting the cardiovascular system. Factor XII (FXII, Hageman factor) is a plasma protease that initiates the contact system. The biochemistry of the contact system in vitro is well understood; however, its in vivo functions are just beginning to emerge. The current review concentrates on activators and functions of the FXII-driven contact system in vivo. Elucidating its physiologic activities offers the exciting opportunity to develop strategies for the safe interference with both thrombotic and inflammatory diseases.